Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Department of Medical Oncology, Jinling Clinical College of Nanjing Medical University, Nanjing, China.
Cell Death Differ. 2018 Dec;25(12):2209-2220. doi: 10.1038/s41418-018-0123-6. Epub 2018 May 29.
Androgen receptor (AR) is emerging as a novel prognostic biomarker in triple-negative breast cancer (TNBC), but the underlying mechanisms remain unknown. As accumulating evidence has shown that long non-coding RNAs (lncRNAs) regulate important cancer hallmarks, we hypothesised that AR-regulated lncRNAs might play roles in TNBC progression. Here, we performed experiments with or without DHT treatment in three TNBC cell lines, and we identified an AR negatively induced lncRNA (ARNILA), which correlated with poor progression-free survival (PFS) in TNBC patients and promoted epithelial-mesenchymal transition (EMT), invasion and metastasis in vitro and in vivo. Subsequently, we demonstrated that ARNILA functioned as a competing endogenous RNA (ceRNA) for miR-204 to facilitate expression of its target gene Sox4, which is known to induce EMT and contribute to breast cancer progression, thereby promoting EMT, invasion and metastasis of TNBC. Our findings not only provide new insights into the mechanisms of lncRNA in regulating AR but also suggest ARNILA as an alternative therapeutic target to suppress metastasis of TNBC patients.
雄激素受体 (AR) 正成为三阴性乳腺癌 (TNBC) 的一种新的预后生物标志物,但潜在机制尚不清楚。有越来越多的证据表明,长非编码 RNA (lncRNA) 调节重要的癌症特征,因此我们假设 AR 调节的 lncRNA 可能在 TNBC 进展中发挥作用。在这里,我们在三种 TNBC 细胞系中进行了有或没有 DHT 处理的实验,鉴定出一种 AR 负诱导的 lncRNA (ARNILA),其与 TNBC 患者的无进展生存期 (PFS) 较差相关,并促进体外和体内的上皮-间充质转化 (EMT)、侵袭和转移。随后,我们证明 ARNILA 作为 miR-204 的竞争性内源性 RNA (ceRNA) 发挥作用,以促进其靶基因 Sox4 的表达,已知 Sox4 诱导 EMT 并有助于乳腺癌进展,从而促进 TNBC 的 EMT、侵袭和转移。我们的研究结果不仅为 lncRNA 调节 AR 的机制提供了新的见解,还表明 ARNILA 是抑制 TNBC 患者转移的另一种治疗靶点。